Apnimed Sells Joint Venture Stake for $150 Million to Focus on AD109 Development Apnimed has sold its stake in a joint venture with Shionogi for $150M, strengthening its focus on the development of AD109 for obstructive sleep apnea.

Apnimed Sells Joint Venture Stake for $150 Million to Focus on AD109 Development #USA #Cambridge #Apnimed #AD109 #Shionogi

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 Apnimed will present new Phase 3 data for AD109, an innovative oral medication for obstructive sleep apnea, at the CHEST 2025 meeting in Chicago.

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 #United_States #Chicago #Obstructive_Sleep_Apnea #Apnimed #AD109

Apnimed to Showcase Groundbreaking OSA Treatments at CHEST 2025 Annual Meeting Apnimed, Inc. will present innovative Phase 3 data for AD109 at the CHEST Annual Meeting, addressing urgent needs in obstructive sleep apnea.

Apnimed to Showcase Groundbreaking OSA Treatments at CHEST 2025 Annual Meeting #United_States #Chicago #Apnimed #OSA #AD109

Apnimed Set to Engage Investors at Key September Conferences Focused on Sleep Disorders Apnimed, Inc. announces its participation in upcoming investor conferences focusing on sleep-related disorders and pioneering oral treatments.

Apnimed Set to Engage Investors at Key September Conferences Focused on Sleep Disorders #United_States #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 At the World Sleep Congress 2025, Apnimed will present its groundbreaking oral therapy, AD109, aimed at alleviating obstructive sleep apnea.

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 #United_States #Cambridge #Obstructive_Sleep_Apnea #Apnimed #AD109

Promising Results for Apnimed's AD109 in Obstructive Sleep Apnea Clinical Trials Apnimed's AD109 shows positive Phase 3 trial results for obstructive sleep apnea, offering hope for millions who need effective treatment options.

Promising Results for Apnimed's AD109 in Obstructive Sleep Apnea Clinical Trials #United_States #Cambridge #Apnimed #OSA #AD109

Apnimed's Upcoming Investor Conferences: Pioneering Sleep Apnea Treatments Apnimed, a clinical-stage pharmaceutical company, highlights its presence at major investor conferences in July, focusing on innovative sleep apnea treatments.

Apnimed's Upcoming Investor Conferences: Pioneering Sleep Apnea Treatments #United_States #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed Achieves Landmark Phase 3 Clinical Trial Results for AD109 in Obstructive Sleep Apnea Treatment Apnimed has reported promising results from its Phase 3 clinical trial of AD109, a new oral treatment for obstructive sleep apnea, marking a potential shift in patient care.

Apnimed Achieves Landmark Phase 3 Clinical Trial Results for AD109 in Obstructive Sleep Apnea Treatment #USA #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed Prepares for Major Presentations at the 2025 ATS Conference on Sleep Medicine Innovations Apnimed, Inc. has announced multiple presentations at the upcoming ATS International Conference in San Francisco, showcasing advances in sleep medicine.

Apnimed Prepares for Major Presentations at the 2025 ATS Conference on Sleep Medicine Innovations #United_States #San_Francisco #Apnimed #AD109 #ATS2025

Apnimed Announces Breakthrough in Sleep Apnea Treatment with Clinical Updates on SASS-001 and AD109 Trials Apnimed has made significant strides in sleep apnea treatment, with updates on SASS-001 and AD109 trials, promising new options for patients.

Apnimed Announces Breakthrough in Sleep Apnea Treatment with Clinical Updates on SASS-001 and AD109 Trials #United_States #Cambridge #Apnimed #SASS-001 #AD109